Quantcast

Latest Fluticasone/salmeterol Stories

2008-12-12 05:12:52

A U.S. Food and Drug Administration panel said the drugs Serevent and Foradil shouldn't be used for treating asthma. The panel said Serevent and Foradil are often prescribed inappropriately by doctors and used incorrectly by patients, The New York Times said Thursday. The drugs are longer-acting beta agonists intended to prevent attacks but have been shown to increase the risk of more severe attacks if used without a steroid, the newspaper said. The panel ruled that Advair and Symbicort...

2008-12-11 16:04:00

WASHINGTON, Dec. 11 /PRNewswire-FirstCall/ -- The following is GlaxoSmithKline's (NYSE: GSK) statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK's Serevent(R) (salmeterol) and Advair(R) (salmeterol/fluticasone proprionate). "We welcome the committee's endorsement of Advair as a safe and effective treatment for asthma in adults and children," said Dr. Ellen Strahlman, Chief...

2008-12-10 13:07:00

MENLO PARK, Calif., Dec. 10 /PRNewswire/ -- As part of the broader public discussion around asthma sparked by the FDA's examination of the commonly prescribed asthma drugs Advair, Symbicort, Serevent and Foradil, Dr. Philip Marcus, Chief, Division of Pulmonary Medicine, St. Francis Hospital, and Dr. James Wolfe, of Allergist, Allergy and Asthma Associates of Northern California, are available to discuss exhaled nitric oxide monitoring as an essential addition to asthma treatment,...

d9cbf5228b14efb44c88ae5aa9bdfd0b1
2008-12-10 10:47:21

Recently, millions of asthma patients have begun taking long-acting drugs to allow them to breathe a bit more normally, which allow them to experience continual sleep in the evenings or workouts at the gym. At the moment, the Food and Drug Administration is examining if these medications could increase the risk of severe asthma problems. At a meeting on Wednesday, independent medical advisers will review the scientific facts and make a decision on if the drugs should continue to be used in...

2008-12-01 07:00:00

WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline's Advair is declining in all lines of therapy for newly diagnosed asthma patients. The new report entitled Treatment Algorithms in Asthma shows a reduction in Advair use in first-, second- and third-lines of therapy to 12.2 percent, 13.6 percent, and 14.6 percent, respectively...

2008-10-31 12:00:32

GlaxoSmithKline has announced that data from a three-year study of patients with chronic obstructive pulmonary disease found that the inhaled corticosteroid in Advair Diskus 250/50, fluticasone propionate, did not show an adverse effect on bone mineral density measured at the lumbar spine and total hip compared to salmeterol alone. In this study, designed to show equivalent rate of change in bone mineral density (BMD) for Advair and salmeterol, results for bone mineral density in the lumbar...

2008-10-29 15:00:10

PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that data from a three-year study of patients with Chronic Obstructive Pulmonary Disease (COPD) found that the inhaled corticosteroid in Advair Diskus 250/50, fluticasone propionate, did not show an adverse effect on bone mineral density (BMD) measured at the lumbar spine and total hip compared to salmeterol alone. In this study, designed to show equivalent rate of change in BMD for Advair and salmeterol,...

2008-10-23 03:00:40

SkyePharma Announces Successful Completion of FlutiformTM U.S. Clinical Trial Programme LONDON, UK, 23 October, 2008 - SkyePharma PLC (LSE: SKP) today announces that the final U.S. Phase III efficacy study evaluating FlutiformTM for the treatment of moderate to severe asthma in adolescent and adult patients has met its primary endpoint. The study is the last Phase III clinical efficacy study to be carried out in preparation for regulatory filing. In a top line analysis of key results, the...

2008-09-09 12:00:42

Sepracor, a research-based pharmaceutical company, has announced that Alvesco HFA inhalation aerosol metered-dose inhaler is now available by prescription in the US. Alvesco HFA is a new inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. This asthma treatment is available in 80mcg/actuation and 160mcg/actuation dosage strengths. Adrian Adams, president and CEO of Sepracor, said: "Our...

2008-08-05 12:01:07

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma http://www.reportlinker.com/p091764/Stakeholder-Insight-Asthma---Over-prescribing-is-common-in-intermittent-and-mild-forms-of-asthma.html Introduction Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.